These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 20377145)

  • 1. The efficacy of low-dose intranasal scopolamine for motion sickness.
    Simmons RG; Phillips JB; Lojewski RA; Wang Z; Boyd JL; Putcha L
    Aviat Space Environ Med; 2010 Apr; 81(4):405-12. PubMed ID: 20377145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intranasal Scopolamine for Motion Sickness.
    Stankovic AS; Alvarenga DL; Coleman Daniels VR; Simmons RG; Buckey JC; Putcha L
    Aerosp Med Hum Perform; 2019 Nov; 90(11):917-924. PubMed ID: 31666152
    [No Abstract]   [Full Text] [Related]  

  • 3. Modafinil as a potential motion sickness countermeasure.
    Hoyt RE; Lawson BD; McGee HA; Strompolis ML; McClellan MA
    Aviat Space Environ Med; 2009 Aug; 80(8):709-15. PubMed ID: 19653573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose escalation pharmacokinetics of intranasal scopolamine gel formulation.
    Wu L; Boyd JL; Daniels V; Wang Z; Chow DS; Putcha L
    J Clin Pharmacol; 2015 Feb; 55(2):195-203. PubMed ID: 25187210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Various anti-motion sickness drugs and core body temperature changes.
    Cheung B; Nakashima AM; Hofer KD
    Aviat Space Environ Med; 2011 Apr; 82(4):409-15. PubMed ID: 21485398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of double-dose transdermal scopolamine.
    Bar R; Gil A; Tal D
    Pharmacotherapy; 2009 Sep; 29(9):1082-8. PubMed ID: 19698013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the effects of a selective muscarinic receptor antagonist and hyoscine (scopolamine) on motion sickness, skin conductance and heart rate.
    Golding JF; Stott JR
    Br J Clin Pharmacol; 1997 Jun; 43(6):633-7. PubMed ID: 9205824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transdermal scopolamine, oral meclizine, and placebo in motion sickness.
    Dahl E; Offer-Ohlsen D; Lillevold PE; Sandvik L
    Clin Pharmacol Ther; 1984 Jul; 36(1):116-20. PubMed ID: 6734040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transdermal scopolamine in the prevention of motion sickness at sea.
    Price NM; Schmitt LG; McGuire J; Shaw JE; Trobough G
    Clin Pharmacol Ther; 1981 Mar; 29(3):414-9. PubMed ID: 7009021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Restricted sedation and absence of cognitive impairments after administration of intranasal scopolamine.
    Weerts AP; Pattyn N; Putcha L; Hoag SW; Van Ombergen A; Hallgren E; Van de Heyning PH; Wuyts FL
    J Psychopharmacol; 2015 Dec; 29(12):1231-5. PubMed ID: 26268532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Scopolamine nasal spray in motion sickness: a randomised, controlled, and crossover study for the comparison of two scopolamine nasal sprays with oral dimenhydrinate and placebo.
    Klöcker N; Hanschke W; Toussaint S; Verse T
    Eur J Pharm Sci; 2001 May; 13(2):227-32. PubMed ID: 11297908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of experimental motion sickness by scopolamine absorbed through the skin.
    Graybiel A; Knepton J; Shaw J
    Aviat Space Environ Med; 1976 Oct; 47(10):1096-100. PubMed ID: 791234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transdermal scopolamine in motion sickness.
    Cronin CM; Sallan SE; Wolfe L
    Pharmacotherapy; 1982; 2(1):29-31. PubMed ID: 6927209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transdermal scopolamine in the prevention of motion sickness: evaluation of the time course of efficacy.
    Homick JL; Kohl RL; Reschke MF; Degioanni J; Cintron-Trevino NM
    Aviat Space Environ Med; 1983 Nov; 54(11):994-1000. PubMed ID: 6651736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug treatment of motion sickness: scopolamine alone and combined with ephedrine in real and simulated situations.
    Tokola O; Laitinen LA; Aho J; Gothoni G; Vapaatalo H
    Aviat Space Environ Med; 1984 Jul; 55(7):636-41. PubMed ID: 6466260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticholinergic Versus Antihistaminic Treatment for Simulator Sickness Prevention.
    Ben-Ari O; Sarfati S; Gordon B; Assa A; Nakdimon I
    J Clin Pharmacol; 2023 Oct; 63(10):1119-1125. PubMed ID: 37491788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of motion sickness in parabolic flight with buccal scopolamine.
    Norfleet WT; Degioanni JJ; Calkins DS; Reschke MF; Bungo MW; Kutyna FA; Homick JL
    Aviat Space Environ Med; 1992 Jan; 63(1):46-51. PubMed ID: 1550533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of transdermally administered scopolamine in preventing motion sickness.
    McCauley ME; Royal JW; Shaw JE; Schmitt LG
    Aviat Space Environ Med; 1979 Nov; 50(11):1108-11. PubMed ID: 393242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histaminergic response to Coriolis stimulation: implication for transdermal scopolamine therapy of motion sickness.
    Wang ET; Zhou DR; He LH
    Aviat Space Environ Med; 1992 Jul; 63(7):579-82. PubMed ID: 1616432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of the selective muscarinic M3 receptor antagonist darifenacin, and of hyoscine (scopolamine), on motion sickness, skin conductance & cognitive function.
    Golding JF; Wesnes KA; Leaker BR
    Br J Clin Pharmacol; 2018 Jul; 84(7):1535-1543. PubMed ID: 29522648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.